Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4/A Registration of securities issued in business combination transactions
- 5.1 Opinion of Ellenoff Grossman & Schole LLP.
- 8.1 Form of Tax Opinion of Ellenoff Grossman & Schole LLP.
- 23.1 Consent of Marcum LLP
- 23.2 Consent of Turner, Stone & Company, LLP
- 99.1 Form of Proxy Card for Shareholders.
- 99.3 Consent of Vantage Point.
- 99.6 Consent of Tara Maria Desilva to Be Named As a Director.
- 99.7 Consent of Philippe Deschamps to Be Named As a Director.
- 99.8 Consent of Christopher Cochran to Be Named As a Director.
- 99.9 Consent of Gene Salkind to Be Named As a Director.
- Download Excel data file
- View Excel data file
Associated filings
- 3 Oct 22 EFFECT Notice of effectiveness
- 30 Sep 22 424B3 Prospectus supplement
- 29 Sep 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 26 Sep 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 12 Sep 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 22 Aug 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 27 Jul 22 S-4/A Registration of securities issued in business combination transactions (amended)
-
5 Jul 22 S-4/A Registration of securities issued in business combination transactions (amended)
- 25 May 22 S-4 Registration of securities issued in business combination transactions
COEP similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We have issued our report dated March 10, 2022 with respect to the financial statements of Coeptis Therapeutics, Inc. contained in the Amendment No. 1 to Form S-4 Registration Statement and Proxy Statement/Prospectus. We consent to the use of our aforementioned report in the Amendment No. 1 to Form S-4 Registration Statement and Proxy Statement/Prospectus, and to the use of our name as it appears under the caption “Experts.”
/s/ TURNER, STONE & COMPANY, LLP
Dallas, Texas
July 5, 2022